Nominations have closed and we have more than two dozen nominations for Stem Cell Person of the Year 2014. It’s an exciting, diverse group including some news faces as well as nominees from years past as well. Happy Stem Cell Day! You can now vote for your choice for the top finalists in the poll […]
Stem Cell Person of the Year 2014 Award: Vote To Choose 12 Finalists Read More »
Stem cell biotech BioTime announced the news today that its subsidiary Cell Cure Neurosciences (Cell Cure) has filed an IND with the FDA for an embryonic stem (ES) cell-based therapy for Dry age-related macular degeneration (AMD). The product to be tested is OpRegen, which the company indicates is “the first IND for an ES cell-based
BioTime Cell Cure Files IND with FDA for ES cell AMD therapy Read More »
Nominations are now open for the 2014 Stem Cell Person of the Year Award. The winner receives $2,000 as well as recognition as a true difference maker and leader in the stem cell field. I found the first two years of this award process that all the finalists received a great deal of positive attention
Nominations Open for 2014 Stem Cell Person of the Year with $2,000 Prize Read More »
I invited Neuralstem CEO, Richard Garr, to do a Q&A interview and he kindly accepted. The interview provides some novel insights into this major biotech in the stem cell sector. 1. How is Neuralstem doing today? What programs are underway that you find particularly exciting? Garr: Neuralstem is moving on all cylinders these days on
Interview with Neuralstem CEO Richard Garr Read More »
Below is a list of upcoming stem cell and regenerative medicine conferences and meetings in 2015. If you do not see your meeting, please let me know and I will include it. This list is meant to be as inclusive as possible, but by listing specific events I am not necessarily endorsing them. Enjoy! January
Stem Cell Meetings & Conferences 2015 Read More »
StemCells Inc. is a top biotech company developing stem cell-based therapies. They have a deep pipeline that includes already ongoing trials for a variety of diseases. I invited company leadership to do an interview and they graciously accepted. Below is the interview with CFO Greg Schiffman (picture at left from LinkedIn) including what I thought
Interview with StemCells Inc. leadership on hot topics Read More »
What are the most interesting questions for the stem cell field in 2014 right now? What’s on your mind? I’m not going to give this deep thought, but rather just list those questions bouncing around at the moment in no particular order. You can see a lot of translational/clinical things are on my mind. I’ve
Key questions for stem cell field bouncing around on a Friday morning Read More »
Type 1 Diabetes is a huge global problem. Where are the solutions that would compliment or replace insulin therapy for diabetics? There haven’t been too many that have gotten very far, which makes the news of a potential stem cell-based therapy moving along in the pipeline all the more exciting. ViaCyte (see more posts here,
Great News: FDA Nod For ViaCyte IND of Diabetes Stem Cell-Based Product Read More »
What the heck happened to the FDA when it comes to regulating stem cell clinics? Has it given up? Or does it just seem that way because it moves in slow motion? The FDA might as well have thrown in the towel because, as I like to say, the stem cell field moves in dog years.
Has the FDA given up on regulating stem cell clinics? Read More »
StemCells, Inc. is one of those stem cell-related biotech companies that we in the field hope will become a big success and help many patients in the future via stem cell technology. There are a lot of obstacles facing such companies. Some are privately held, while others such as StemCells, Inc. are publicly traded (stock
StemCells, Inc. Faces Lawsuit With Serious Allegations Read More »